RxDoctor Payments Data

Patricia Damron-Robinson, NP

Adult Health · Merrillville, INNPI 1831343870

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,807 of the $19,897 with a category attached, or 69.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 20.8%. Among adult health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,897in general payments, 2019–2025

Across 549 payments — averaging $36.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Incyte Corporation$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$926
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$5403%
  • Food & beverage$13,80769%
  • Education$1,90610%
  • Other$3,64418%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis66$4,133
AstraZeneca(2 entities)59$2,385
Johnson & Johnson(2 entities)39$1,527
Incyte Corporation36$1,364
E.r. Squibb & Sons, L.L.C.27$1,203
Pfizer18$926
Genentech USA, Inc.26$696
Amgen24$594
Seagen Inc.12$573
Daiichi Sankyo Inc.13$474
Bristol Myers Squibb20$471
Intrinsiq Specialty Solutions, Inc.4$382
Astellas Pharma US Inc17$373
Jazz Pharmaceuticals Inc.10$350
Takeda Pharmaceuticals U.S.A., Inc.12$338
Merck15$296
Regeneron Healthcare Solutions, Inc.11$289
AbbVie13$239
Gilead(2 entities)8$235
Mirati Therapeutics, Inc.7$231
Pharmacyclics LLC, An Abbvie Company6$204
Exelixis Inc.5$163
Sanofi8$161
GSK9$155
Beone Medicines USA, Inc.1$149
Ipsen Biopharmaceuticals, Inc6$147
Sobi, Inc7$131
Celltrion USA Inc.2$130
EMD Serono, Inc.3$115
ASD Specialty Healthcare, LLC1$95
Pharmacosmos Therapeutics Inc.3$83
Array Biopharma Inc4$82
Eisai Inc.4$77
Stemline Therapeutics Inc.3$76
Lilly USA, LLC3$73
Puma Biotechnology, Inc.4$70
Coherus Oncology, Inc.3$68
Pharmaessentia USA Corporation2$54
Sumitomo Pharma America, Inc.2$53
Clovis Oncology, Inc.3$52
Myovant Sciences Inc.2$51
Global Blood Therapeutics, Inc.2$44
Azurity Pharmaceuticals, Inc.2$43
Rigel Pharmaceuticals, Inc.2$42
Octapharma USA, Inc.2$42
Bayer2$40
Amneal Pharmaceuticals LLC2$40
Deciphera Pharmaceuticals Inc.2$38
Syndax Pharmaceuticals, Inc.1$31
Morphosys, US Inc.2$30
Taiho Oncology, Inc.2$29
Agios Pharmaceuticals, Inc.1$29
Medtronic1$27
Fennec Pharmaceuticals, Inc.1$26
EUSA Pharma (US) LLC1$25
Blueprint Medicines Corporation1$23
Curium US LLC1$21
Mayne Pharma Commercial LLC1$21
Boehringer Ingelheim1$19
Beigene USA, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,897 in reported general payments places this provider in the 95th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$160,065
Medicare patients
132
Services billed
5,635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide29$477,718
PomalystPomalidomide13$322,715
JakafiRuxolitinib Phosphate17$296,664
RevlimidLenalidomide16$279,568
VenclextaVenetoclax19$240,210
Imatinib Mesylate24$44,429
EliquisApixaban49$40,102
XareltoRivaroxaban33$25,499
Exemestane11$4,006
Fentanyl25$3,200
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$1,743
Ondansetron Hcl12$1,456
Hydroxyurea45$1,075
Acyclovir61$1,046
Anastrozole63$908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$1,203$322,71513 claims
Incyte CorporationJakafi$1,364$296,66417 claims
Bristol Myers SquibbRevlimid$471$279,56816 claims
AbbVieVenclexta$239$240,21019 claims
PfizerEliquis$926$40,10249 claims
Johnson & JohnsonXarelto$1,527$25,49933 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$40$13220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 adult health providers in Indiana.

Other adult health in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →